In April 2026, Dr Jane Ruth Aceng at a Ministry of Health function held at Lira Regional Referral Hospital, officially launched the rollout of Lenacapavir, a long-acting injectable drug aimed at strengthening HIV prevention efforts in Uganda.

Unlike a vaccine, Lenacapavir is a form of pre-exposure prophylaxis (PrEP) designed to protect HIV-negative individuals from acquiring HIV. The medication is administered as an injection twice a year, offering a long-term alternative to daily oral PrEP pills. The introduction of Lenacapavir marks another significant development in Uganda’s HIV prevention strategy, adding a long-acting option to existing prevention methods.

According to the rollout plan, a single injection will provide protection for up to six months, with the drug reported to offer up to 99 percent protection against HIV when used as prescribed.

Phased Rollout Begins

The Ministry of Health officially launched the first phase of distribution in Lira, beginning with an initial batch of nearly 20,000 doses. The rollout will initially focus on high-burden districts and selected health facilities before expanding to other parts of the country.

Lenacapavir will first be available through specialised clinics and selected military health facilities, including GMH Bombo. More than 100 health facilities have already been prepared and trained to support the programme, with plans to expand access to 300 facilities nationwide by the end of 2026.

The injectable drug is expected to particularly benefit HIV-negative individuals who are at an elevated risk of HIV infection, especially those who struggle to consistently take daily oral PrEP. Daily medication can present challenges ranging from forgetfulness and busy schedules to concerns about privacy and social stigma. The twice-yearly injection could therefore provide a more convenient and discreet option for people who need HIV prevention but find it difficult to maintain a daily pill routine.

As the programme expands across the country, health authorities hope that increased access to the injectable PrEP drug will help reach vulnerable populations and contribute to the wider effort to reduce new HIV infections in Uganda.